Clinical Trial

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2025 (before its estimated February 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-05; most recent amendment 2025-11-20.
Status change: Recruiting → Active, Not Recruiting 2025-11-20
Status change: Not Yet Recruiting → Recruiting 2025-04-02
Trial Details
NCT Number NCT06767748
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Diabetes
Enrollment 620 participants
Start Date 2025-02-15
Primary Completion 2026-02-07 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-11-21